Published in J Med Genet on July 01, 2005
Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol (2007) 7.46
Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proc Natl Acad Sci U S A (2006) 1.99
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A (2014) 1.95
Assessment of functional effects of unclassified genetic variants. Hum Mutat (2008) 1.69
Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer (2008) 1.61
Update on familial pancreatic cancer. Adv Surg (2010) 1.54
Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control. EPMA J (2010) 1.52
Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin Cancer Res (2012) 1.47
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer (2012) 1.39
BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res (2005) 1.31
Pathology of hereditary breast cancer. Cell Oncol (Dordr) (2011) 1.28
Prevalence of the most frequent BRCA1 mutations in Polish population. J Appl Genet (2011) 1.12
The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. Int J Cancer (2011) 1.06
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res (2006) 1.01
Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome. Hered Cancer Clin Pract (2011) 1.00
The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30-49. Eur J Health Econ (2007) 0.99
Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. J Natl Cancer Inst (2014) 0.99
Hereditary breast cancer in Middle Eastern and North African (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. Mol Biol Rep (2011) 0.95
Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status. J Med Genet (2005) 0.92
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol (2012) 0.91
Age-dependent penetrance of different germline mutations in the BRCA1 gene. J Clin Pathol (2009) 0.91
BRCA2 mutations and triple-negative breast cancer. PLoS One (2012) 0.89
Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. Fam Cancer (2008) 0.84
A new mutation of BRCA2 gene in an Italian healthy woman with familial breast cancer history. Fam Cancer (2011) 0.83
Is it time to offer BRCA1 and BRCA2 testing to all Jewish women? Curr Oncol (2015) 0.81
Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. Fam Cancer (2008) 0.79
Hereditary breast and ovarian cancer. Hered Cancer Clin Pract (2008) 0.77
Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK. Fam Cancer (2015) 0.77
Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers. J Clin Oncol (2015) 0.75
Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer. Br J Cancer (2015) 0.75
Selected aspects of genetic counselling for BRCA1 mutation carriers. Hered Cancer Clin Pract (2007) 0.75
Novel polymorphisms in caspase-8 are associated with breast cancer risk in the California Teachers Study. BMC Cancer (2016) 0.75
Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London. Fam Cancer (2012) 0.75
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer (1977) 53.23
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer (1976) 22.55
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst (1995) 18.86
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Plasmid-controlled colonization factor associated with virulence in Esherichia coli enterotoxigenic for humans. Infect Immun (1975) 14.65
Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med (1991) 12.89
Hemagglutination of human group A erythrocytes by enterotoxigenic Escherichia coli isolated from adults with diarrhea: correlation with colonization factor. Infect Immun (1977) 10.84
Production of vascular permeability factor by enterotoxigenic Escherichia coli isolated from man. Infect Immun (1973) 9.99
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
New surface-associated heat-labile colonization factor antigen (CFA/II) produced by enterotoxigenic Escherichia coli of serogroups O6 and O8. Infect Immun (1978) 8.52
Differences in the response of rabbit small intestine to heat-labile and heat-stable enterotoxins of Escherichia coli. Infect Immun (1973) 8.47
Extensions to multivariate normal models for pedigree analysis. Ann Hum Genet (1982) 7.07
Survival of patients with breast cancer attending Bristol Cancer Help Centre. Lancet (1990) 7.04
Cohort study analysis with a FORTRAN computer program. Int J Epidemiol (1986) 6.66
Stimulation of adenyl cyclase by Escherichia coli enterotoxin. Nat New Biol (1972) 6.65
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med (1992) 6.64
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst (1999) 6.48
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst (1994) 6.27
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet (2005) 6.18
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA (1996) 5.95
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Detection and characterization of colonization factor of enterotoxigenic Escherichia coli isolated from adults with diarrhea. Infect Immun (1978) 5.71
Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J (1979) 5.58
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J (2003) 5.53
Travelers' diarrhea and toxigenic Escherichia coli. N Engl J Med (1975) 5.20
Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet (1987) 5.02
Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology (1991) 4.86
Treatment differences and other prognostic factors related to breast cancer survival. Delivery systems and medical outcomes. JAMA (1994) 4.86
Polymyxin B-Induced Release of Low-Molecular-Weight, Heat-Labile Enterotoxin from Escherichia coli. Infect Immun (1974) 4.79
Hemagglutination patterns of enterotoxigenic and enteropathogenic Escherichia coli determined with human, bovine, chicken, and guinea pig erythrocytes in the presence and absence of mannose. Infect Immun (1979) 4.60
TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer (1995) 4.59
Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer (1997) 4.47
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA (1995) 4.45
Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol (1997) 4.43
Three characteristics associated with enterotoxigenic Escherichia coli isolated from man. Infect Immun (1973) 4.42
A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet (1996) 4.38
Purification and characterization of the CFA/I antigen of enterotoxigenic Escherichia coli. Infect Immun (1979) 4.24
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J (2003) 4.20
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer (2002) 4.18
Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst (1997) 4.09
Identification of enterotoxigenic Escherichia coli and serum antitoxin activity by the vascular permeability factor assay. Infect Immun (1973) 4.07
The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer (2004) 4.06
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87